Modified Toxin to Treat Obesity?

Researchers show that a synthetic peptide derived from a sea anemone toxin has potent weight-regulating effects in a mouse model of obesity.

Written byDan Cossins
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

A Caribbean sun anemone (Stichodactyla helianthus)WIKIMEDIA, OMAR SPENCE PHOTOGRAPHYA slightly modified synthetic version of a peptide found in the toxin of Caribbean sun anemones boosts metabolic activity in obese mice fed a junk-food diet, according to a study published this week (May 27) in the Proceedings of the National Academy of Sciences. The results indicate that the compound, known as Shk-186, which is already a promising drug candidate for the treatment of several autoimmune diseases, could also be developed as a potential treatment for obesity and insulin resistance in humans.

Developed by George Chandy of the University of California, Irvine, and colleagues, Shk-186 potently and specifically blocks the Kv1.3 potassium channel on T-lymphocyte cells, the upregulation of which is implicated in autoimmune diseases. (For more on Shk-186 and other toxin-derived drugs, see our recent story “From Toxins to Therapeutics.”) However, potassium channels control various cellular processes and previous studies had suggested that Kv1.3 might also regulate metabolic rate and body weight, so Chandy decided to see what effects the tailored peptide, which passed Phase 1 safety trials in March, would have on overweight mice.

In tests on mice fed a high-fat, high-sugar diet, treatment with ShK-186 reduced weight gain, white fat deposits, fatty liver, blood cholesterol, and blood sugar, the researchers reported. They think it ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies